Home › Compare › HHULF vs ABBV
HHULF yields 0.63% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, HHULF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HHULF + ABBV for your $10,000?
Hamburger Hafen und Logistik Aktiengesellschaft operates as a port and transport logistics company in Germany, rest of European Union, and internationally. It operates through four segments: Container, Intermodal, Logistics, and Real Estate. The company operates three container terminals in Hamburg; and container terminals in Odessa, Ukraine, and Tallinn, Estonia, as well as in Trieste, Italy. It also offers intermodal services that connect ports on the North and Baltic seas, and between the Northern Adriatic and its hinterland, as well as inland terminals. In addition, the company provides specialist handling, digital, and consulting and management services; and process automation, additive manufacturing, and airborne logistics services, as well as develops, rents, and manages real estate properties. The company was formerly known as Hamburger Hafen- und Lagerhaus-AG and changed its name to Hamburger Hafen und Logistik Aktiengesellschaft in 2005. The company was founded in 1885 and is headquartered in Hamburg, Germany. Hamburger Hafen und Logistik Aktiengesellschaft is a subsidiary of HGV Hamburger Gesellschaft für Vermögens- und Beteiligungsmanagement mbH.
Full HHULF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.